Gene Therapy
Gene therapy delivers a working copy of a gene, or a correction to a faulty one, usually once and for life. Manufacturing the delivery vector is often harder than designing the therapy.
131 stocks
| # | Name | Holding | Trade Value |
Theme Stocks |
% of Portfolio | Status | |
|---|---|---|---|---|---|---|---|
| 51 |
Adage Capital Partners
Boston,
Massachusetts
| $322M | +$24M | 17 | 0.74% | Increased |
|
| 52 |
Alkeon Capital Management
New York
| $321M | +$16M | 4 | 0.87% | Increased |
|
| 53 |
NMC
NEA Management Company
Timonium,
Maryland
| $314M | +$48.4M | 7 | 16.1% | Increased |
|
| 54 |
Macquarie Group
Sydney, NSW 2000,
Australia
| $309M | +$7.52M | 31 | 0.35% | Increased |
|
| 55 |
Citadel Advisors
Miami,
Florida
| $308M | -$85.8M | 80 | 0.08% | Reduced |
|
| 56 |
HA
HHLR Advisors
Grand Cayman,
Cayman Islands
| $307M | -$133M | 4 | 6.58% | Reduced |
|
| 57 |
Allspring Global Investments
Charlotte,
North Carolina
| $305M | +$152M | 23 | 0.51% | Increased |
|
| 58 |
Royal Bank of Canada
Toronto,
Ontario, Canada
| $303M | -$17.8M | 75 | 0.09% | Reduced |
|
| 59 |
UBS Group
Zurich,
Switzerland
| $297M | -$90.8M | 91 | 0.12% | Reduced |
|
| 60 |
Nuveen
Charlotte,
North Carolina
| $290M | -$26.3M | 37 | 0.11% | Reduced |
|
| 61 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
| $288M | +$29M | 5 | 14.2% | Increased |
|
| 62 |
Cullen Capital Management
New York
| $284M | +$5.97M | 1 | 2.86% | Increased |
|
| 63 |
Millennium Management
New York
| $283M | -$72M | 82 | 0.18% | Reduced |
|
| 64 |
Kohlberg Kravis Roberts & Co
New York
| $282M | $0 | 2 | 3.75% | Maintained |
|
| 65 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| $278M | +$25.6M | 51 | 0.16% | Increased |
|
| 66 |
Sands Capital Management
Arlington,
Virginia
| $278M | -$78.9M | 1 | 0.96% | Reduced |
|
| 67 |
Two Sigma Investments
New York
| $277M | -$69M | 43 | 0.91% | Reduced |
|
| 68 |
BBA
Baker Bros. Advisors
New York
| $273M | -$42.8M | 18 | 1.55% | Reduced |
|
| 69 |
Credit Suisse
Zurich,
Switzerland
| $272M | -$24.6M | 57 | 0.28% | Reduced |
|
| 70 |
CC
Casdin Capital
New York
| $269M | -$53.3M | 8 | 22.7% | Reduced |
|
| 71 |
D.E. Shaw & Co
New York
| $267M | -$26M | 51 | 0.31% | Reduced |
|
| 72 |
Principal Financial Group
Des Moines,
Iowa
| $265M | -$3.37M | 28 | 0.2% | Reduced |
|
| 73 |
FP
Flagship Pioneering
Cambridge,
Massachusetts
| $261M | $0 | 3 | 9.85% | Maintained |
|
| 74 |
OrbiMed
New York
| $251M | -$19.6M | 10 | 4.54% | Reduced |
|
| 75 |
Legal & General Group
London,
United Kingdom
| $250M | +$7.25M | 49 | 0.09% | Increased |
|